Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the possibility of discontinuing TKI treatment. We have...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Zhang, Bin, Chu, Su, Agarwal, Puneet, Campbell, Victoria L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Gaal, Karl, Holyoake, Tessa L., Bhatia, Ravi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2016
Gaiak:
Myeloid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5146743/
https://ncbi.nlm.nih.gov/pubmed/27621307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-679928
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak